Researchers at City of Hope National Medical Center have won a $13 million grant to fund a clinical trial employing CAR-T cell immunotherapy to kill brain cancer, hospital officials announced this week.
The world-renowned cancer treatment center in Duarte received $12.8 million from the California Institute of Regenerative Medicine to fund a Phase 1 clinical trial to combat an aggressive brain cancer called malignant glioma.
The trial, led by Christine Brown, PhD, and Dr. Behnam Badie, will employ the CAR-T cell-based therapy in which a patient’s own T cells are reprogrammed to seek out and destroy malignant cells. It will be open to adults and children.
Few therapies exist for malignant glioma, which has a five-year survival rate of 5.5 percent.
City of Hope was the first and only cancer center to treat patients with chimeric antigen receptor (CAR) T cells to target a protein found in most glioblastomas. It was also the first to administer CAR-T therapy in the brain.
The California Institute for Regenerative Medicine, a public institute based in Oakland, was launched by California’s Stem Cell Agency as a result of Proposition 71 approved by voters in 2004. Of its $3 billion in dedicated funds, some $500 million is left to support stem cell research and cures across the state.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- City of Hope Receives $3.7M to Conduct Stem Cell Research on Brain Cancer
- PeproMene Bio Receives $40 Million
- City of Hope Adding to Stem Cell Capabilities
- Family of City of Hope Dynamo Gives $1 Million to Spur CART Cancer Therapy
- UCLA Launches First-of-Its-Kind Stem Cell Trial to Combat Cancer
- UCLA and City of Hope Receive $2.8 Million in Grants for Stem Cell Research
- City of Hope Lands Nearly $6M Grant for Stem Cell Study for Sickle Cell Disease
- Children’s Hospital to Lead Immunotherapy Study